Lannett digoxen use in clinics unlikely to change, says Canaccord Canaccord said the use of Lannett's digoxen drug was only prescribed to critically ill Afib patients so the mortality risk cited in a retrospective study by Turakhia is not surprising. Given the risk of thrombotic events from Afib progression far outweighing the mortality risk the firm sees little change to clinical practice. Shares of Lannett are Buy rated with a $55 price target.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.